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bolus administration of nitric oxide
donors and calcium channel antag-
onists has been proposed to reduce
cerebral vasospasm (CVS) in animal
subarachnoid hemorrhage (SAH)
models. Intrathecal continuous ad-
ministration of these substances
for CVS prevention has not been
extensively evaluated. This study
compared the efficacy of continuous
intrathecal infusions of the NO donor
glyceroltrinitrate and nimodipine in
preventing delayed CVS associated
with SAH in an animal model in
vivo. Methods: New Zealand White
rabbits were randomly assigned to six
groups: no SAH/NaCl, no SAH/NO,
no SAH/nimodipine, SAH/NaCl,
SAH/NO, or SAH/nimodipine. Glyc-
eroltrinitrate (GTN) at 0.5 µg/µl
(0.5 µl/h) or nimodipine at 0.2 µg/µl
(10 µl/h) or NaCl was continuously
infused into the cisterna magna
via an Alzet osmotic pump from
day 0 to day 5 after injection of
1.0 ml autologous blood. The mag-
nitude of spasm in the basilar artery
was determined by comparison of
pre- and posttreatment angiography
and was calculated as proportional
change in intraluminal diameter
based on automatic measurements.
Results: A total of 55 experiments
and 110 angiograms were performed.
SAH was associated with vaso-
constriction of the basilar artery
(SAH/NaCl group 19.85 ± 2.94%).
Continuous intrathecal injection of
GTN and nimodipine prevented
SAH-induced CVS. There was
significant prevention of CVS in
animals treated with GTN (SAH/NO
group 5.93 ± 5.2%, n = 11) and ni-
modipine (SAH/nimodipine group:
0.55 ± 2.66%, n = 9). There was no
significant difference between the
treatment groups and controls in pre-
vention of CVS. Conclusions: This
study demonstrates that prophylactic
continuous intrathecal administration
of either GTN or nimodipine equally
prevents SAH-associated CVS in an
animal model.
Keywords Subarachnoid hemor-
rhage · Vasospasm · Animal models ·
Nitric oxide · Nimodipine
Introduction
Symptomatic delayed cerebral vasospasm (DCV) develops
in approx. 30% of patients after aneurysmal subarachnoid
hemorrhage (SAH) and remains one of the major causes
of serious morbidity and death [1, 2]. Brain ischemic
events secondary to cerebral vasospasm (CVS) classically
occur 4–12 days after initial bleeding [3]. The exact cause
of CVS is unknown despite awareness of the entity for
almost half a century. Although the treatment protocol of
hypervolemia, hemodilution, and hypertension (“triple-H
therapy”) in combination with intravenous nimodipine ad-
ministration has had a substantial beneficial effect in CVS
treatment [4], in some patients the protocol is not tolerated
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or is ineffective [5–7]. Despite our increased knowledge
of the molecular basis of DCV following SAH no current
treatment modalities offer prophylactic prevention. Pre-
liminary case series in humans [8–11] and experimental
studies in a variety of animal models [12–17] suggest
that intrathecal administration of an NO donor would
be an effective treatment for reversing CVS. Controlled-
release polymers such as diethyl-amine-triamine/NO
and ethylene-vinyl acetate copolymer implanted in the
subarachnoid space close to the experimental bleeding site
serve as NO donors in most recent animal models with
intrathecal administration of the drugs [12–18]. Further-
more, sodium nitroprusside (SNP) and glyceroltrinitrate
(GTN) have served as NO donor to prevent CVS after
SAH [8–11, 19, 20].
Nimodipine, the most widely administered calcium
channel blocker, is a dihydropyridine calcium channel
antagonist that has been shown to decrease the incidence
of overall cerebral infarction after SAH by 34% and
the incidence of poor outcomes by 40% [21]. Whereas
intravenous or oral administration of nimodipine does not
appear to decrease the incidence of angiographic CVS [22,
23], intraoperative bathing of vessels in nimodipine solu-
tion and intrathecal bolus administration has demonstrated
reversal of spasm and dilatation of nonspastic vessels,
without changes in mean arterial blood pressure [24–29].
The present study compared the efficacy of continuous
intrathecal infusions of the NO donor glyceroltrinitrate
and nimodipine in preventing CVS in the rabbit SAH
model in vivo.
Materials and methods
The protocol of this study was reviewed and approved by
the Swiss Institutional Animal Care and Use Committee
Body PaCO2 PaO2 MABP HR
weight (kg) (mmHg) (mmHg) (mmHg) (per min)
no SAH/NaCl
Day 0 3.6 ± 0.1 51.70 ± 0.95 50.52 ± 8.6 65.5 ± 4.04 162 ± 5
Day 5 3.6 ± 0.1 43.60 ± 3.30 57.20 ± 1.3 56.20 ± 6.64 174 ± 7
no SAH/NO
Day 0 3.7 ± 0.2 44.00 ± 1.97 54.72 ± 3.7 64.33 ± 2.89 157 ± 4
Day 5 3.7 ± 0.2 45.75 ± 7.34 57.31 ± 4.1 55.33 ± 4.96 155 ± 8
no SAH/nimodipine
Day 0 2.7 ± 0.1 49.43 ± 1.82 63.24 ± 4.2 77.83 ± 3.43 178 ± 10
Day 5 2.7 ± 0.1 50.23 ± 1.77 61.04 ± 4.9 70.50 ± 2.62 181 ± 6
SAH/NaCl
Day 0 3.8 ± 0.2 45.37 ± 1.63 67.27 ± 5.2 72.50 ± 3.95 163 ± 4
Day 5 3.8 ± 0.2 41.36 ± 3.68 63.07 ± 4.1 59.83 ± 2.68 171 ± 7
SAH/NO
Day 0 3.8 ± 0.1 43.52 ± 2.16 64.80 ± 3.2 67.33 ± 3.40 179 ± 5
Day 5 3.8 ± 0.1 44.03 ± 2.57 62.98 ± 8.5 65.00 ± 4.95 163 ± 7
SAH/nimodipine
Day 0 3.1 ± 0.2 48.68 ± 1.43 67.05 ± 3.4 75.83 ± 2.52 191 ± 9
Day 5 3.1 ± 0.2 48.30 ± 1.68 74.07 ± 6.5 71.17 ± 2.09 178 ± 7
Table 1 Measurements of
physiological parameters
(PaCO2, arterial carbon dioxide
pressure; PaO2, arterial oxide
pressure; MABP, mean arterial
blood pressure; HR, heart rate)
and meets the Swiss guidelines for laboratory animal use
(Department of Veterinary Service, Berne, Switzerland,
approval no. 125/05).
Study design
A total of 55 adult New Zealand White rabbits of either sex
weighing 2.6–3.6 kg were randomly assigned to six exper-
imental groups. The groups did not differ significantly in
body weight, PaCO2, mean arterial blood pressure, or heart
rate at baseline (day 0) or at follow-up (day 5; Table 1).
Anesthesia, monitoring, and killing
Induction of general anesthesia was performed by
intramuscular administration of ketamine (30 mg/kg;
Ketalar, 50 mg/ml, Pfizer, Zurich, Switzerland) and xy-
lazine (6 mg/kg; Xylapan 20 mg/ml, Vetoquinol, Bern,
Switzerland). During surgery pain was evaluated pe-
riodically by toe-pinch. Postoperative pain relief was
managed by subcutaneous administration of buprenor-
phine (0.1–0.2 mg/kg) for up to 36 h after SAH. Heart rate
and blood pressure were monitored throughout the digital
subtraction angiography (DSA) on day 0 and day 5 after
experimental SAH. Intravascular pressures and heart rate
were measured with a Camino multiparameter monitor
(Integra, Plainsboro, NJ, USA). On the same days arterial
blood gas status was analyzed to monitor oxygenation
parameters from a collected arterial blood sample (ABL
725, Radiometer, Copenhagen, Denmark). The animals
underwent daily clinical observation. The animals were
killed on day 5 post-SAH induction under the same anes-
thetic as the angiography by intra-arterial bolus injection
of sodium thiopenthal (40 mg/kg) (Pentothal, Ospedalia,
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Hünenberg, Switzerland). Postmortem examination of
operative scars, pump, and tube position was performed
to evaluate signs of infection and to affirm correct sil-
icone catheter connection to the pump and unchanged
catheter location within the subarachnoid space of the
atlanto-occipital cistern.
Angiography
DSA was performed under general anesthesia on day 0
prior to SAH and on day 5 post-SAH. The rabbit’s left
(day 0) or right (day 5) subclavian artery was microsur-
gically exposed and cannulated using a 0.5 mm plastic
tube. The catheter was introduced retrogradely and fixed
distally to the origin of the vertebral artery. Subsequently
the DSA was performed by intra-arterial bolus injection of
nonionic iopamidol (0.6 ml/kg; Abott Laboratories, North
Chicago, IL, USA) as contrast agent. Images of the verte-
brobasilar system were obtained using a rapid sequential
angiographic technique with the small focal spot at 66 kV,
125 mA (DFP 2000A, Toshiba, Japan). Measurement
of each vessel was performed three times in a blinded
fashion by using the automatic measurement tool of the
ImagePro Discovery analysis software (MediaCybernet-
ics, Silver Spring, MD, USA), and mean values were
determined.
Induction of experimental SAH
Following baseline DSA on day 0, the atlanto-occipital
membrane was exposed, and a 25-gauge needle was
inserted into the cerebromedullar cistern. After relief of
1.0 ml CSF an equal amount of unheparinized autologous
arterial blood was injected into the cistern under micro-
scopic view. The rabbits were kept positioned at a 65°
angle head-down for 10 min to allow blood dissemination
throughout the subarachnoidal space (Fig. 1).
Miniosmotic pump implantation
Depending on the study group, a miniosmotic pump
(0.5 µl/h, Alzet Osmotic Pumps, Durect, Cupertino, CA,
USA) containing 0.5 mg/ml GTN solution (Perlinganit,
Schwarz Pharma, Münchenstein, Switzerland) or a min-
iosmotic pump (10 µl/h, Alzet) containing 0.2 mg/ml
nimodipine solution (Nimotop, Bayer HealthCare, Co-
logne, Germany) was implanted subcutaneously. Dose-
response curves of intrathecal GTN and nimodipine are
not available. The dose of GTN was derived from studies
in humans in which up to 8 mg/24 h was used for prophy-
laxis against vasospasm [8, 9]. The pH value of the GTN
and nimodipine solution was 7.35 and 7.4, respectively.
The dose of nimodipine was calculated from studies in
Fig. 1 Axial computer tomography demonstrates the successful dis-
semination of blood after cisterna magna injection. Arrow, Hyper-
dense prepontine blood collection
canine models [26, 27]. The rabbit’s CSF volume was
estimated to be 70–80 times less than that in humans
and 5–10 times less than that in dogs [30, 31]. Pumps,
associated tubing, and drugs were protected from light
at all times. A silicone catheter (STH-C040, Connectors
Verbindungstechnik, Tagelswangen, Switzerland) was
connected with the pump and inserted at least 1 mm
through the atlanto-occipital membrane into the subarach-
noid space. The tube insertion site was sealed by a muscle
patch and fixed by several stitches. The midline spinal
muscle incision was closed in two layers. Finally, the
wounds were superficially irrigated with neomycin sulfate
(Research Organics, Cleveland, OH, USA) for infection
prophylaxis. All surgical procedures were performed
under sterile conditions.
Statistical methods
Values were expressed as means of each group ± SEM
(n = number of animals). Statistical significance between
two means was determined by Student’s unpaired t test
and significance between multiple means was determined
by analysis of variance.
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Results
Mortality, morbidity, and neurological status
Two animals died immediately after injection of auto-
logous blood into the atlanto-occipital cistern as a result
of respiratory arrest. All other animals were in bland
neurological condition after the angiographic and surgi-
cal procedures and did not develop delayed neurological
deficits, with the exception of one animal in the SAH/NaCl
control group, which exhibited transient paresis of the
hind legs on day 2 after experimental SAH. Clinical daily
follow-up of the animals was uneventful up to day 5 when
they were killed. Gross pathological evaluation revealed
no signs of infection. All of the implanted pump devices
were placed in accurate position 1–2 mm underneath the
atlanto-occipital membrane.
Angiographic measurements
A total of 110 angiographic vessel diameters of the
rabbit basilar artery were investigated in the six groups.
Angiographic measurements and diameter changes in per-
centages are given in Table 2 and Fig. 2, respectively. The
baseline vessels’ diameter on day 0 did not differ signifi-
cantly among the six experimental groups. The data show
that SAH and plain saline infusion were associated with
vasoconstriction of the basilar artery (SAH/NaCl group
19.85 ± 2.94%; no SAH/NaCl group 14.92 ± 4.49%;
Table 2). The continuous intrathecal infusion of both ni-
modipine and GTN significantly reduced SAH-associated
vasoconstriction (SAH/nimodipine 0.55 ± 2.66%, n = 9,
vs. SAH/NaCl 19.85 ± 2.94%, n = 8, p < 0.005; SAH/NO
5.93 ± 5.2%, n = 11, vs. SAH/NaCl:19.85 ± 2.94%, n = 8,
p < 0.05). The comparison of the effects of nimodipine
and GTN on diameter changes after SAH showed no
statistical difference.
Discussion
The results of this study demonstrate nearly complete
prevention of delayed CVS of the rabbit basilar artery in
response to continuous intrathecal infusion of GTN or
n Diameter (µm) Diameter
Day 0 Day 5 reduction (%)
no SAH/NaCl 11 669.51 ± 2.97 593.59 ± 3.03 14.92 ± 4.49
no SAH/NO 9 676.03 ± 1.27 625.18 ± 1.14 5.67 ± 2.92
no SAH/nimodipine 7 730.04 ± 2.60 733.88 ± 5.90 0.32 ± 2.30
SAH/NaCl 8 688.71 ± 1.81 542.60 ± 1.70 19.85 ± 2.94
SAH/NO 11 648.21 ± 1.38 637.26 ± 2.26 5.93 ± 5.20**
SAH/nimodipine 9 726.58 ± 3.85 713.68 ± 3.18 0.55 ± 2.66*
*p < 0.001, **p < 0.05 vs. control group SAH/NaCl
Table 2 Summary of the effect
of continuous intrathecal nitro-
glycerin and nimodipine infusion
on basilar artery caliber (µm) in
rabbits with experimental SAH.
Values are expressed as the
mean ± standard error of mean
Fig. 2 Bar graph shows the results of the effect of continuous in-
tracisternal administration of nitric oxide donor (nitroglycerin) and
nimodipine on cerebral vasospasm after experimental subarrachnoid
hemorrhage in rabbits in vivo. The SAH/NO donor group (n = 11)
and the SAH/nimodipine group (n = 9) both demonstrate significant
prevention (**p = 0.0031, ***p = 0.0002) of the basilar artery
spasm compared to the control SAH/Saline group (n = 8) 5 days
postexperimental subarrachnoid hemorrhage. There was no signif-
icant (p = 0.3741) difference in the efficacy of spasm reduction
between the SAH/NO donor group and the SAH/nimodipine group.
There was also no significant difference between the no SAH/NO
group (n = 9) and the SAH/NO group (p = 0.9622) or between the
no SAH/nimodipine (n = 7) group and the SAH/nimodipine group
(p = 0.9507). Nimo, Nimodipine
nimodipine and therefore confirms previous promising re-
sults with intrathecal use of these two compounds [12–17,
24–29, 32]. In the presented experimental setting they
showed no significant difference in their efficacy.
NO is the smallest biologically active molecule known.
As a highly diffusible gas it mediates an extraordinary
range of physiological processes [33, 34]. The role of
NO in the context of SAH began when the identity of
the hypothetical endothelium-derived relaxing factor and
NO was recognized [35–37]. Ongoing research revealed
further extensive roles of NO in neurotransmission, in-
flammation, and vascular autoregulation [38]. In particular
NO appears to decrease vascular inflammation (one of
the key pathways in delayed CVS) [39, 40], serves as
a high potent vasodilating agent [41], and regulates the
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cerebral vascular tone as antagonist of the most potent
vasoconstrictor ET-1 [42]. Due to the short half-life,
side effects, and potential toxicity of NO in clinical
use, investigators in the past have focused on treating
experimental CVS by using intrathecal and periadventitial
soluble administration or polymer placements of NO
and NOD (see Table 1, see ESM) [12–17]. Most of the
performed animal studies used diethylenetriamine nitric
oxide donor from a controlled release polymer to pre-
vent CVS after experimental SAH [13, 15–17]. Thomas
et al. [8] and Kumar et al. [11] published preliminary
results of effective treatment of intrathecal bolus adminis-
tration of SNP in patients with established delayed CVS.
Raabe et al. [10] studied the effect of SNP in patients with
severe, medically refractory vasospasm. They suggested
that SNP is more effective when initiated early and admin-
istered continuously.
The highly lipid-soluble calcium antagonist nimodip-
ine has been advocated in the treatment of cerebral
vasospasm because it inhibits a fundamental mechanism
involved in vasoconstriction of cerebral arteries, calcium
influx. The influx of extracellular calcium ions results
from the opening of L type calcium channels (target
of calcium antagonists) and additional channels such
as store operated-channels [43]. Lack of prevention of
CVS and systemic side effects with oral or intravenous
administration led to experiments with topical application.
Voldby et al. [26] studied the effect of intrathecal bolus
administration of calcium antagonist nimodipine after
experimental SAH in dogs. Nimodipine always relieved
spasm and often the relaxation surpassed the resting
vessel diameter, whereas in a control group the injection
of placebo did not relax the spastic arteries [26]. Goia
et al. [27] and Zabramski et al. [32] found beneficial
effect on intrathecal nimodipine as opposed to systemic
administration in reversing angiographic vasospasm in
the two-hemorrhage and multihemorrhage canine models.
Based on these promising data derived from experimental
studies on topical nimodipine, first clinical trials have
been carried out using perivascular administration of
the drug [24, 25, 28]. Despite promising results form
these trials and previous experimental studies (Table 2,
ESM) [24–29, 32], intrathecal administration of nimodip-
ine as a potential avenue in CVS prevention remained
controversial and fall into oblivion [29].
Not only the systemic side effects of current treatment
modalities but also the trend towards endovascular treat-
ment of ruptured aneurysms has influenced research into
alternatives for treating CVS after SAH [44, 45]. During
the procedure of craniotomy and aneurysm clipping the
vessels surrounding the bleeding site are accessible for top-
ical drug application or deposition of a polymer or place-
ment of a tube for repeated drug administration. Methods
which require surgical access to the region of interest are
less likely to be used in a patient treated with endovascu-
lar coiling. Other approaches are likely to generate more
interest, such as administration through lumbar puncture
and advancement of a microcatheter and microguidewire
to the ventral cisterna magna under fluoroscopic visualiza-
tion or administration via conventional external ventricular
drain.
In bleeding sites, independently of intrathecal drug ap-
plication, the ability of the drug to reach the target may be
impaired by clotting or abnormal cerebrospinal fluid cir-
culation. Thomas et al. [8, 9] argue that the drug (in their
experiment SNP) may penetrate the brain parenchyma by
way of the ventricle’s ependyma. In this hypothesis the
drug becomes independent of ventricular CSF circulation
but still does not bypass the problem of clot penetration. It
remains unclear whether a high drug concentration in close
vicinity to the clot is necessary.
In the presented model intrathecal administration is
carried out at the same location where the experimental
SAH occurred. Nearly all experiments performed are
based on this principle of drug administration at the bleed-
ing site. This selectivity is barely conceivable in a clinical
setting. Therefore the results from the current study should
be evaluated in a model in which the SAH bleeding site is
independent of the intrathecal drug administration.
The remarkable vasospasms in the control group (no
SAH/NaCl) may have occurred due to aseptic inflamma-
tory response to mechanical disruption [46]. In the begin-
ning of experimental CVS research mechanical stimula-
tion was used to induce arterial narrowing [46, 47]. Other
authors with a similar setting of continuous intracisternal
drug infusion to attenuate SAH induced CVS do not re-
port a control group of saline infusion and therefore the
possibility to compare our findings lacks [48]. However,
the results indicate that the placement of drug administra-
tion devices in the vicinity of the examined vessel could
be unfavorable. Independent location of drug administra-
tion from the bleeding site would avoid any local interac-
tion and drug penetration to the affected vessel could be
determined. Eligible would be the use of a ventriculosub-
arachnoid cannula, with the possibility of continuous drug
administration and simultaneous measurement of intracra-
nial pressure through the same cranial screw device [49].
In this set-up possible side effects of additional fluid de-
rived from drug administration can be monitored by the
ICP parameter.
The results show no statistically significant difference
between no SAH/treatment and SAH/treatment groups,
which indicates that both nimodipine and GTN are potent
in preventing delayed cerebral vasospasm associated with
either experimental SAH or pump implantation. In the
current understanding of delayed cerebral vasospasm
nimodipine and NO donor GTN are acting at the bot-
tom of the pathophysiological cascade and may prevent
vasospasm on an unspecific basis, irrespective of the
initially underlying cause (chemical stimulation by sub-
arachnoid blood or mechanical stimulation by pump im-
plantation).
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The findings of this study warrant further investigations
into the dose-dependency effects of continuous intrathecal
infusion NO donors and nimodipine in a modified rabbit
model with intraventricular drug delivery. Based on current
clinical treatment modalities after SAH, an experimental
setting with an intrathecal administration site that differs
from the bleeding site is needed to confirm these results as
a potential preventive treatment option in SAH-associated
CVS.
Acknowledgements. We gratefully thank Hans Rudolf Widmer,
PhD, and Jürgen Schmid, RN, from the Department of Neuro-
surgery, University Hospital Berne, for their professional laboratory
support.
References
1. Brisman JL, Song JK, Newell DW
(2006) Cerebral aneurysms. N Engl J
Med 355:928–939
2. Al-Yamany M, Wallace MC (1999)
Management of cerebral vasospasm
in patients with aneurysmal subarach-
noid hemorrhage. Intensive Care Med
25:1463–1466
3. Biller J, Godersky JC, Adams HP Jr
(1988) Management of aneurysmal
subarachnoid hemorrhage. Stroke
19:1300–1305
4. Sen J, Belli A, Albon H, Morgan L,
Petzold A, Kitchen N (2003) Triple-H
therapy in the management of aneurys-
mal subarachnoid haemorrhage. Lancet
Neurol 2:614–621
5. Porchet F, Chiolero R, de Tribolet N
(1995) Hypotensive effect of nimodip-
ine during treatment for aneurysmal
subarachnoid haemorrhage. Acta
Neurochir (Wien) 137:62–69
6. Stiefel MF, Heuer GG, Abrahams JM,
Bloom S, Smith MJ, Maloney-
Wilensky E, Grady MS, LeRoux PD
(2004) The effect of nimodipine on
cerebral oxygenation in patients with
poor-grade subarachnoid hemorrhage.
J Neurosurg 101:594–599
7. Subramani K, Ghrew M (2004) Severe
myocardial depression following in-
travenous nimodipine for aneurysmal
subarachnoid haemorrhage. Intensive
Care Med 30:1498–1499
8. Thomas JE, Rosenwasser RH, Ar-
monda RA, Harrop J, Mitchell W,
Galaria I (1999) Safety of intrathecal
sodium nitroprusside for the treatment
and prevention of refractory cerebral
vasospasm and ischemia in humans.
Stroke 30:1409–1416
9. Thomas JE, Rosenwasser RH (1999)
Reversal of severe cerebral vasospasm
in three patients after aneurysmal
subarachnoid hemorrhage: initial
observations regarding the use of
intraventricular sodium nitroprusside in
humans. Neurosurgery 44:48–57
10. Raabe A, Zimmermann M, Setzer M,
Vatter H, Berkefeld J, Seifert V (2002)
Effect of intraventricular sodium nitro-
prusside on cerebral hemodynamics and
oxygenation in poor-grade aneurysm
patients with severe, medically re-
fractory vasospasm. Neurosurgery
50:1006–1013
11. Kumar R, Pathak A, Mathuriya SN,
Khandelwal N (2003) Intraventricular
sodium nitroprusside therapy: a future
promise for refractory subarachnoid
hemorrhage-induced vasospasm.
Neurol India 51:197–202
12. Wolf EW, Banerjee A, Soble-Smith J,
Dohan FC Jr, White RP, Robertson JT
(1998) Reversal of cerebral vasospasm
using an intrathecally administered
nitric oxide donor. J Neurosurg
89:279–288
13. Gabikian P, Clatterbuck RE, Eber-
hart CG, Tyler BM, Tierney TS,
Tamargo RJ (2002) Prevention of
experimental cerebral vasospasm by
intracranial delivery of a nitric oxide
donor from a controlled-release poly-
mer: toxicity and efficacy studies in
rabbits and rats. Stroke 33:2681–2686
14. Aihara Y, Jahromi BS, Yassari R,
Sayama T, Macdonald RL (2003)
Effects of a nitric oxide donor on
and correlation of changes in cyclic
nucleotide levels with experimental
vasospasm. Neurosurgery 52:661–667
15. Pradilla G, Thai QA, Legnani FG,
Hsu W, Kretzer RM, Wang PP,
Tamargo RJ (2004) Delayed intracra-
nial delivery of a nitric oxide donor
from a controlled-release polymer pre-
vents experimental cerebral vasospasm
in rabbits. Neurosurgery 55:1393–1399
16. Clatterbuck RE, Gailloud P, Tier-
ney T, Clatterbuck VM, Murphy KJ,
Tamargo RJ (2005) Controlled release
of a nitric oxide donor for the preven-
tion of delayed cerebral vasospasm
following experimental subarachnoid
hemorrhage in nonhuman primates.
J Neurosurg 103:745–751
17. Tierney TS, Pradilla G, Wang PP,
Clatterbuck RE, Tamargo RJ (2006)
Intracranial delivery of the nitric oxide
donor diethylenetriamine/nitric oxide
from a controlled-release polymer:
toxicity in cynomolgus monkeys.
Neurosurgery 58:952–960
18. Suzuki Y, Osuka K, Noda A,
Tanazawa T, Takayasu M, Shibuya M,
Yoshida J (1997) Nitric oxide metabo-
lites in the cisternal cerebral spinal
fluid of patients with subarachnoid
hemorrhage. Neurosurgery 41:807–811
19. Thomas JE, Nemirovsky A, Zelman V,
Giannotta SL (1997) Rapid reversal of
endothelin-1-induced cerebral vasocon-
striction by intrathecal administration
of nitric oxide donors. Neurosurgery
40:1245–1249
20. Macdonald RL, Zhang ZD, Curry D,
Elas M, Aihara Y, Halpern H,
Jahromi BS, Johns L (2002) Intra-
cisternal sodium nitroprusside fails
to prevent vasospasm in nonhuman
primates. Neurosurgery 51:761–768
21. Pickard JD, Murray GD, Illingworth R,
Shaw MD, Teasdale GM, Foy PM,
Humphrey PR, Lang DA, Nelson R,
Richards P et al. (1989) Effect of oral
nimodipine on cerebral infarction and
outcome after subarachnoid haemor-
rhage: British aneurysm nimodipine
trial. BMJ 298:636–642
22. Tettenborn D, Dycka J, Volberg E,
Dudden P (1985) Blood pressure and
heart rate during treatment with ni-
modipine in patients with subarachnoid
hemorrhage. Neurochirurgia (Stuttg) 28
[Suppl 1]:84–86
23. Tettenborn D, Dycka J (1990) Preven-
tion and treatment of delayed ischemic
dysfunction in patients with aneurysmal
subarachnoid hemorrhage. Stroke
21:IV85–IV89
24. Auer LM, Ito Z, Suzuki A, Ohta H
(1982) Prevention of symptomatic
vasospasm by topically applied ni-
modipine. Acta Neurochir (Wien)
63:297–302
938
25. Auer LM (1984) Acute operation and
preventive nimodipine improve out-
come in patients with ruptured cerebral
aneurysms. Neurosurgery 15:57–66
26. Voldby B, Petersen OF, Buhl M, Jakob-
sen P, Ostergaard R (1984) Reversal of
cerebral arterial spasm by intrathecal
administration of a calcium antagonist
(nimodipine). Acta Neurochir (Wien)
70:243–254
27. Gioia AE, White RP, Bakhtian B,
Robertson JT (1985) Evaluation of
the efficacy of intrathecal nimodipine
in canine models of chronic cerebral
vasospasm. J Neurosurg 62:721–728
28. Auer LM, Brandt L, Ebeling U,
Gilsbach J, Groeger U, Harders A,
Ljunggren B, Oppel F, Reulen HJ,
Saeveland H (1986) Nimodipine and
early aneurysm operation in good
condition SAH patients. Acta Neurochir
(Wien) 82:7–13
29. Lewis PJ, Weir BK, Nosko MG,
Tanabe T, Grace MG (1988) Intrathe-
cal nimodipine therapy in a primate
model of chronic cerebral vasospasm.
Neurosurgery 22:492–500
30. Artru AA, Momota T (2000) Rate
of CSF formation and resistance to
reabsorption of CSF during sevoflurane
or remifentanil in rabbits. J Neurosurg
Anesthesiol 12:37–43
31. Zoghbi HY, Okumura S, Laurent JP,
Fishman MA (1985) Acute effect of
glycerol on net cerebrospinal fluid
production in dogs. J Neurosurg
63:759–762
32. Zabramski J, Spetzler RF, Bonstelle C
(1986) Chronic cerebral vasospasm:
effect of calcium antagonists. Neuro-
surgery 18:129–135
33. Nathan C, Xie QW (1994) Nitric oxide
synthases: roles, tolls, and controls.
Cell 78:915–918
34. Koshland DE Jr (1992) The molecule
of the year. Science 258:1861
35. Hanggi D, Steiger HJ (2006) Nitric
oxide in subarachnoid haemorrhage
and its therapeutics implications. Acta
Neurochir (Wien) 148:605–613
36. Kim P, Lorenz RR, Sundt TM Jr,
Vanhoutte PM (1989) Release of
endothelium-derived relaxing fac-
tor after subarachnoid hemorrhage.
J Neurosurg 70:108–114
37. Marin J, Sanchez-Ferrer CF (1990)
Role of endothelium-formed nitric
oxide on vascular responses. Gen
Pharmacol 21:575–587
38. Anggard E (1994) Nitric oxide: medi-
ator, murderer, and medicine. Lancet
343:1199–1206
39. Berendji-Grun D, Kolb-Bachofen V,
Kroncke KD (2001) Nitric oxide in-
hibits endothelial IL-1[beta]-induced
ICAM-1 gene expression at the tran-
scriptional level decreasing Sp1 and
AP-1 activity. Mol Med 7:748–754
40. Oshiro EM, Hoffman PA, Dietsch GN,
Watts MC, Pardoll DM, Tamargo RJ
(1997) Inhibition of experimental
vasospasm with anti-intercellular adhe-
sion molecule-1 monoclonal antibody
in rats. Stroke 28:2031–2037
41. Pluta RM (2005) Delayed cerebral
vasospasm and nitric oxide: review, new
hypothesis, and proposed treatment.
Pharmacol Ther 105:23–56
42. Faraci FM (1990) Role of nitric oxide
in regulation of basilar artery tone in
vivo. Am J Physiol 259:H1216–H1221
43. Zuccarello M, Boccaletti R, Tosun M,
Rapoport RM (1996) Role of extra-
cellular Ca2+ in subarachnoid hem-
orrhage-induced spasm of the rabbit
basilar artery. Stroke 27:1896–1902
44. Molyneux AJ, Kerr RS, Yu LM,
Clarke M, Sneade M, Yarnold JA,
Sandercock P (2005) International
subarachnoid aneurysm trial (ISAT)
of neurosurgical clipping versus en-
dovascular coiling in 2143 patients
with ruptured intracranial aneurysms:
a randomised comparison of effects
on survival, dependency, seizures,
rebleeding, subgroups, and aneurysm
occlusion. Lancet 366:809–817
45. Citerio G, Gaini SM, Tomei G, Stoc-
chetti N (2007) Management of 350
aneurysmal subarachnoid hemorrhages
in 22 Italian neurosurgical centers.
Intensive Care Med 33:1580–1586
46. Blaumanis OR, Grady PA (1982)
Experimental cerebral vasospasm:
resolution by chlorpromazine. Surg
Neurol 17:263–268
47. Endo S, Suzuki J (1979) Experimental
cerebral vasospasm after subarachnoid
hemorrhage. Participation of adrenergic
nerves in cerebral vessel wall. Stroke
10:703–711
48. Zuccarello M, Boccaletti R, Romano A,
Rapoport RM (1998) Endothelin B
receptor antagonists attenuate sub-
arachnoid hemorrhage-induced cerebral
vasospasm. Stroke 29:1924–1929
49. Gyring JA, Brondsted HE (1984)
Repetitive measurements of intracranial
pressure in awake rabbits. Acta Physiol
Scand 122:299–305
